The research will initially focus on applications for acute myeloid leukemia and myelodysplastic syndromes to enhance cytogenetic workflows.
Nabsys and the Indiana University School of Medicine have announced a multi-year research collaboration to develop and evaluate electronic genome mapping applications for hematologic malignancies.
The collaboration will initially focus on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with the potential to expand to other blood cancers and constitutional disorders over time. Kevin TA Booth, PhD, assistant professor in the department of medical and molecular genetics at Indiana University School of Medicine and clinical laboratory director for Indiana University Genetic Testing Laboratories, will evaluate the OhmX Platform to support the development of these applications.
Structural variation is a central component in many hematologic malignancies. Currently, laboratories often require multiple technologies to characterize genomic abnormalities. Fluorescence in situ hybridization (FISH) investigates a limited number of genomic regions, while conventional karyotyping provides a genome-wide view of structural information but at a lower resolution. The research team will evaluate electronic genome mapping as a complementary method for detecting structural variation within existing cytogenetic research workflows.
“Structural variation remains one of the most important yet technically challenging aspects of cancer genomics,” says Kevin TA Booth, PhD, assistant professor at the Indiana University School of Medicine, in a release. “I’m excited to work with the Nabsys team to evaluate Electronic Genome Mapping in AML and MDS and determine where it can complement existing cytogenetic approaches. Every new technology offers an opportunity to see the genome in a different way. This collaboration has the potential to provide new insights into complex genomic abnormalities and advance how we study and understand structural variation.”
The OhmX Platform uses electronic detection to analyze ultra-long DNA molecules. By utilizing precision electronics instead of optical systems, the technology provides high-resolution structural variant and copy number analysis in a compact format.
“Indiana University has long been recognized for excellence in cytogenetics, molecular genetics, and genomic medicine, making it an outstanding collaborator as we continue advancing Electronic Genome Mapping for hematologic malignancy research,” says Barrett Bready, MD, CEO of Nabsys, in a release. “This collaboration builds on our growing body of work with leading academic laboratories and represents another important step toward developing research applications that address longstanding challenges in structural variant analysis.”
Nabsys will present research regarding progress in electronic genome mapping for hematologic malignancies at the Cancer Genomics Consortium Annual Meeting in Houston, Texas, from Aug 1 to 5, 2026. Through an oral presentation and three scientific posters, the company will demonstrate the platform’s ability to provide integrated genomic insights that complement current cytogenetic approaches.
The OhmX Platform is a research-use-only technology that is commercially available to laboratories.
